Corvus Pharmaceuticals (CRVS) Reaches New 1-Year Low at $7.50

Shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $7.50 and last traded at $8.12, with a volume of 24000 shares. The stock had previously closed at $8.12.

Several research firms have issued reports on CRVS. ValuEngine downgraded Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $20.25.

The firm has a market cap of $187.76 and a price-to-earnings ratio of -3.04.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. raised its holdings in Corvus Pharmaceuticals by 76.0% during the 4th quarter. BlackRock Inc. now owns 669,657 shares of the company’s stock worth $6,937,000 after buying an additional 289,096 shares during the period. Vanguard Group Inc. raised its holdings in Corvus Pharmaceuticals by 37.1% during the 2nd quarter. Vanguard Group Inc. now owns 373,512 shares of the company’s stock worth $4,520,000 after buying an additional 101,013 shares during the period. Renaissance Technologies LLC raised its holdings in Corvus Pharmaceuticals by 20.5% during the 4th quarter. Renaissance Technologies LLC now owns 234,200 shares of the company’s stock worth $2,426,000 after buying an additional 39,900 shares during the period. Northern Trust Corp raised its holdings in Corvus Pharmaceuticals by 97.6% during the 2nd quarter. Northern Trust Corp now owns 86,525 shares of the company’s stock worth $1,047,000 after buying an additional 42,739 shares during the period. Finally, State Street Corp raised its holdings in Corvus Pharmaceuticals by 18.6% during the 2nd quarter. State Street Corp now owns 62,475 shares of the company’s stock worth $756,000 after buying an additional 9,779 shares during the period. Hedge funds and other institutional investors own 84.84% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Corvus Pharmaceuticals (CRVS) Reaches New 1-Year Low at $7.50” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/24/corvus-pharmaceuticals-crvs-reaches-new-1-year-low-at-7-50.html.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply